Point72 Asset Management L.P. Invests $3.95 Million in ProQR Therapeutics (NASDAQ:PRQR)

Point72 Asset Management L.P. purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,491,275 shares of the biopharmaceutical company's stock, valued at approximately $3,952,000. Point72 Asset Management L.P. owned 1.83% of ProQR Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of PRQR. Bank of America Corp DE boosted its holdings in ProQR Therapeutics by 11.8% in the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 8,621 shares during the last quarter. Jane Street Group LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at approximately $30,000. Invesco Ltd. acquired a new stake in ProQR Therapeutics in the 4th quarter valued at approximately $32,000. Prudential Financial Inc. boosted its stake in ProQR Therapeutics by 109.1% during the 4th quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 14,400 shares in the last quarter. Finally, Alpine Global Management LLC bought a new position in ProQR Therapeutics during the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Trading Down 1.2%

PRQR traded down $0.02 on Friday, hitting $1.67. 298,231 shares of the stock traded hands, compared to its average volume of 631,837. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The firm has a market capitalization of $175.71 million, a PE ratio of -5.22 and a beta of 0.35. The business has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $2.26.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. On average, equities research analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PRQR. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Oppenheimer reduced their price objective on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Chardan Capital restated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. Evercore ISI initiated coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They set an "outperform" rating and a $5.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).